Managing cardiotoxicity associated with immune checkpoint inhibitors

Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Upadhrasta, Sireesha, Elias, Hadi, Patel, Keval, Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Medical Association 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450824/
https://www.ncbi.nlm.nih.gov/pubmed/30993259
http://dx.doi.org/10.1016/j.cdtm.2019.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450824/
https://www.ncbi.nlm.nih.gov/pubmed/30993259
http://dx.doi.org/10.1016/j.cdtm.2019.02.004

Ejemplares similares